Nazarian G K, Austin W R, Wegryn S A, Bjarnason H, Stackhouse D J, Castañeda-Zúñiga W R, Hunter D W
Department of Radiology, University of Minnesota Hospital and Clinic, 420 Delaware Street S.E., Minneapolis, MN 55455-0392, USA.
Cardiovasc Intervent Radiol. 1996 Jul-Aug;19(4):227-33. doi: 10.1007/BF02577640.
This retrospective study describes our updated experience in treating venous stenoses and occlusions with metallic endovascular stents.
Gianturco, Palmaz, and Wallstent stents were placed in 55 patients over a 4-year period. Stent sites included the subclavian veins (9), innominate veins (3), superior vena cava (4), inferior vena cava (3), iliac veins (29), femoral veins (5), and portal veins (6). The most common indications for stent placement were malignant stenoses and chronic pelvic venous occlusions. Venoplasty and/or urokinase were used as ancillary therapy. Patients were anticoagulated for 3-6 months. Follow-up included clinical assessment and duplex ultrasound.
Lifetable analysis shows 59%, 63%, and 72% primary, primary assisted, and secondary 1-year patency rates, respectively. The 4-year primary patency rates were the same. Duration of patency depended on the venous site. Death was a complication of stent placement in 2 patients and 12 patients died within 6 months after stent placement from primary disease progression. Although early failures were more common in stents placed across occlusions than stenoses, 1-year secondary patency rates were comparable. Primary patency rates were only slightly lower in patients with malignant obstruction than in patients with benign disease.
Endovascular stent placement provides a nonsurgical alternative for reestablishment of venous flow and symptomatic relief in patients with benign as well as malignant venous obstruction.
本回顾性研究描述了我们使用金属血管内支架治疗静脉狭窄和闭塞的最新经验。
在4年期间,为55例患者置入了朱利厄科支架、帕尔马兹支架和华尔支架。支架置入部位包括锁骨下静脉(9例)、无名静脉(3例)、上腔静脉(4例)、下腔静脉(3例)、髂静脉(29例)、股静脉(5例)和门静脉(6例)。支架置入最常见的适应证是恶性狭窄和慢性盆腔静脉闭塞。血管成形术和/或尿激酶用作辅助治疗。患者接受3 - 6个月的抗凝治疗。随访包括临床评估和双功超声检查。
寿命表分析显示,1年的初次通畅率、初次辅助通畅率和二次通畅率分别为59%、63%和72%。4年的初次通畅率相同。通畅持续时间取决于静脉部位。2例患者死亡是支架置入的并发症,12例患者在支架置入后6个月内死于原发性疾病进展。虽然跨越闭塞置入的支架早期失败比狭窄置入的支架更常见,但1年的二次通畅率相当。恶性梗阻患者的初次通畅率仅略低于良性疾病患者。
血管内支架置入为良性和恶性静脉梗阻患者重建静脉血流和缓解症状提供了一种非手术替代方法。